We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Infra-Red Technology Based Test Can Rapidly Predict Severe COVID-19

By LabMedica International staff writers
Posted on 18 Aug 2021
Print article
Illustration
Illustration
Scientists have developed a way of using infra-red technology to rapidly test which patients are most at risk of becoming severely unwell from COVID-19.

In a small pilot study of COVID-19 patients in India that led by QIMR Berghofer Medical Research Institute (Brisbane, Australia) and the Indian Institute of Technology (Maharashtra, India), the test performed with 85% accuracy. The researchers hope that the test could in future be used to triage patients in areas with large outbreaks of the disease.

The test was developed through an international collaboration between academia and industry using blood samples from 128 COVID-19 patients in Mumbai, India. Infra-red spectra measure the levels of different chemical groups in a sample. The team then used artificial intelligence to develop an algorithm to work out which chemical groups, or ‘signatures’, were correlated with patients who became severely unwell.

“We found there were measurable differences in the infra-red spectra in the patients who became severely unwell. In particular, there were differences in two infra-red regions that correspond to sugar and phosphate chemical groups, as well as primary amines, which occur in specific types of proteins,” said Associate Professor Michelle Hill, head of QIMR Berghofer’s Precision and Systems Biomedicine Research Group.

“We also found that having diabetes was a predictor of becoming severely unwell in this group of patients, so we fed this information into the algorithm. We then tested the algorithm on blood samples from a separate group of 30 patients from Mumbai and found it was 85 per cent accurate in predicting which patients would become severely ill,” Associate Professor Hill said. “However, it did result in more ‘false positives’ than predictions that were based solely on the clinical risk factors of age, sex, hypertension and diabetes. We hope that with more testing we can reduce these false positives.”

“From our study, we can say that there is a correlation between blood chemical signature and becoming severely unwell with COVID-19,” said Professor Sanjeeva Srivastava, head of the Proteomics Facility at the Indian Institute of Technology. She added that the finding that there were chemical differences in more severe COVID-19 cases was consistent with published studies conducted in other countries.

Related Links:
QIMR Berghofer Medical Research Institute
Indian Institute of Technology


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.